Plus Therapeutics has successfully dosed 18 patients in the ReSPECT-LM Phase 1 trial, which focuses on the treatment of leptomeningeal metastases (LM) from solid tumors using rhenium (186Re) obisbemeda.
Synnovation Therapeutics has announced the commencement of dosing for the first patient in their Phase I clinical trial of SNV1521, a PARP1 inhibitor, in patients with solid tumors.
Eilean Therapeutics LLC announced that its Australian subsidiary has received approval from the Human Research Ethics Committee to begin a Phase 1 clinical trial of balamenib (ZE63-0302).
The trial is assessing the efficacy of KVA12123, a VISTA-blocking immunotherapy, both as a standalone treatment and in conjunction with Merck’s KEYTRUDA® (pembrolizumab).
The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, an oral capsule derived from MEAI, for patients with alcohol use disorder (AUD).